CXR Biosciences Ltd. Licenses the Rosetta Resolver Gene Expression Data Analysis System from Rosetta Biosoftware.SEATTLE & DUNDEE, Scotland -- Rosetta Biosoftware announced today that CXR CXR abbr. chest x-ray CXR, n chest x-ray; an image of the thoracic cavity, produced by an irradiation scan of the upper torso. Biosciences Ltd. licensed the Rosetta Resolver[R] system to investigate mechanisms of drug toxicity. CXR Biosciences plans to use the statistical analysis tools in the Resolver system to generate high-quality data to support its toxicological research using transcriptional profiling. "We appreciate Rosetta Biosoftware's strong reputation for developing high-quality data management and statistical software for microarray analysis," said Tom Shepherd Thomas Frederick 'Tom' Shepherd (born December 5, 1889 at Headington Quarry, Oxfordshire; died February 13, 1957 at Norbiton, Kingston upon Thames, Surrey) was an English cricketer. , Ph.D., Chief Executive Officer of CXR Biosciences. "The Resolver system will provide us with a solid platform for determining the toxicological profiles of early-stage compounds, helping us to achieve one of CXR's strategic aims, which is to revolutionize the human risk assessment of drugs and chemicals." "At Rosetta Biosoftware, we developed the Resolver system to be a flexible and scalable framework to grow with a researcher's throughput needs," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "We take pride in developing a robust data management and statistical analysis platform to support our customers. We are pleased to provide the Resolver system to CXR Biosciences to enable toxicology research in a preclinical drug development setting, and to enable CXR to produce reliable results from its data." About CXR Biosciences Ltd. CXR Biosciences Ltd. is a Dundee, Scotland, based company focused on applying advanced molecular and genetic techniques to improve the development of new drugs. This is achieved by developing innovative approaches to improve the predictability and relevance to man of preclinical models. The company is built on the extensive experience in drug development and risk assessment of its founders, Professor Roland Wolf This article is about the luger. For the musician, see Roland Wolf (musician). Roland Wolf was an Austrian luger who competed from the late 1980s to the early 1990s. , and Dr. Cliff Elcombe, of Dundee University. To learn more about CXR Biosciences, visit www.cxrbiosciences.com. About the Rosetta Resolver System The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, formats, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results. Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Sanofi-Aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology California Institute of Technology, at Pasadena, Calif.; originally for men, became coeducational in 1970; founded 1891 as Throop Polytechnic Institute; called Throop College of Technology, 1913–20. . Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com. About Rosetta Biosoftware Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Merck & Co., Inc. (NYSE NYSE See: New York Stock Exchange :MRK MRK Merck & Company (stock symbol) MRK Mayer-Rokitansky-Kuster (anomaly) MRK Manual Remote Keying ). More information about Rosetta Biosoftware is available at www.rosettabio.com. Forward-Looking Statements This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q Form 10-Q See 10-Q. and Form 8-K Form 8-K The form required by the SEC when a publicly held company incurs any event that might affect its financial situation or the share value of its stock. Form 8-K See 8-K. (if any) which are incorporated by reference. Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion